MIRA PHARMACEUTICALS INC (MIRA)

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025

MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA

MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study

MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End

MIRA Stock Earnings: Mira Pharmaceuticals Misses EPS for Q2 2024

MIRA stock results show that Mira Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.

MIRA Stock Earnings: Mira Pharmaceuticals Misses EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Mira Pharmaceuticals (NASDAQ:MIRA) just reported results for the second quarter...

MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor

MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2’s Selective NMDA Binding Mechanism of Action

Why Is Mira Pharmaceuticals (MIRA) Stock Down 27% Today?

Mira Pharmaceuticals stock is falling on Tuesday but that's only after shares of MIRA underwent a massive rally on Monday.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Pre-market stock movers are a hot topic that traders are going to want to know about and we have all of the latest news on Tuesday morning!

Why Is MIRA Pharmaceuticals (MIRA) Stock Up 318% Today?

MIRA Pharmaceuticals stock is up on Monday after the company posted results from a pre-clinical trial of its novel oral ketamine analog.

MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance